FIELD: biotechnology.
SUBSTANCE: highly stable T-cell receptor is proposed that can be used in medicine. The resulting T-cell receptor having mutations in its hydrophobic core domain is used in a pharmaceutical composition for tumour treatment.
EFFECT: invention allows effective therapy of diseases associated with formation of tumours.
25 cl, 49 dwg, 13 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
DOSING REGIMEN FOR A HYBRID PROTEIN GP100-SPECIFIC REDIRECTING TCR-ANTI-CD3 SCFV | 2017 |
|
RU2766119C2 |
MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
Authors
Dates
2018-02-19—Published
2014-06-25—Filed